Plaquenil (hydroxychloroquine 200mg) gained significant popularity primarily due to its potential use in the treatment and prevention of COVID-19 during the early stages of the pandemic. Although originally approved for the treatment of malaria, lupus, and rheumatoid arthritis, generic Plaquenil garnered widespread attention when early studies suggested it might be effective against the SARS-CoV-2 virus. This led to a surge in demand and shortages of the medication, as many sought to stockpile it as a potential prophylactic or therapeutic option against COVID-19. However, subsequent larger clinical trials failed to demonstrate significant benefits of Plaquenil in the management of COVID-19, leading to a reevaluation of its role in the pandemic. Despite its initial popularity, the use of Plaquenil for COVID-19 has since been largely discontinued, and its primary applications remain in the treatment of its approved indications.

What is Plaquenil 200 mg or 400 mg used for? Hydroxychloroquine sulfate is used in the treatment of arthritis to help relieve inflammation, swelling, stiffness, and joint pain and also to help control the symptoms of lupus erythematosus (lupus; SLE). A common brand name for Hydroxychloroquine is Plaquenil. Available in Walmart, CVS, Amazon, Walgreens, Costco.

NewYork-Presbyterian Hospital/Weill Cornell Medical Center is recruiting participants for a multicenter study into a new treatment approach for premenstrual dysphoric disorder (PMDD), a severe and debilitating form of premenstrual syndrome (PMS) that affects up to 8 percent of women. (Read content ‘Participants Recruited For NewYork-Presbyterian/Weill Cornell Study On Premenstrual Dysphoric Disorder’…)

(Read content ‘Model N Announces Industry-First Revenue Planning and Intelligence Solution for Life Science Manufacturers’…)

BlueCielo Showcases InnoCielo FDA Module at 2007 ISPE Annual Meeting

BlueCielo presents compliance with FDA 21 CFR Part 11 regulations with InnoCielo Meridian Enterprise and its FDA Module - November 4-6, 2007, Booth 523 (Event Center), Caesars Palace, Las Vegas, NV.

Las Vegas, NV () November 5, 2007 — BlueCielo ECM Solutions (formerly Cyco Software), a leading global software company offering Engineering Content Management (ECM) solutions, announced today that it is showcasing its innovative ECM solution InnoCielo Meridian Enterprise and its FDA Module at the 2007 ISPE Annual Meeting, a red calendar event for the pharmaceutical and biotechnology manufacturing industries, held November 4-6, 2007 at Booth 523 (Event Center), Caesars Palace, Las Vegas, NV.

(Read content ‘BlueCielo Showcases InnoCielo FDA Module at 2007 ISPE Annual Meeting’…)

Testing Delays Cause Severe AIDS Complications, Researchers Find

ScienceDaily (Nov. 4, 2007) — Despite the availability of life-saving antiretroviral treatment, people infected with HIV (human immunodeficiency virus) continue to die and suffer from complications of AIDS, mainly due to delayed diagnosis and initiation of treatment. (Read content ‘Testing Delays Cause Severe AIDS Complications, Researchers Find’…)

Praxis, a company specializing in centralized patient recruitment for clinical trials, recently provided services to a major pharmaceutical company for a national vaccine research study. (Read content ‘Praxis’ Campaign Saves 12 Weeks Off Enrollment Goal For Women’s Health Vaccine Study’…)

The American Heart Association presented its Chairman’s Award to Ralph L. Sacco, M.D., of Miami, Fla., for his “invaluable leadership” in creating Power To End Stroke, a nationwide educational campaign to raise awareness of the risk of stroke among African Americans. (Read content ‘For Work In Creating Program To Raise Stroke Awareness Among AA, Florida Neurologist Honored’…)

(Read content ‘Epilepsy genes ‘may cut seizures”…)

(Read content ‘Drive to up lung cancer survival’…)

The widely anticipated findings of Lilly and Daiichi Sankyo Co's (4568.T buy stromectol) bid to take on Bristol-Myers Squibb's (BMY.N) Plavix also found the drug, called prasugrel, was significantly more effective in limiting death from cardiovascular events, nonfatal heart attack and strokes.

But the excess bleeding seen with the drug, tested in heart patients with symptoms from severe chest pain to heart attacks, could hurt its chances for regulatory approval and hoped-for blockbuster sales, according to analysts.

The 13,600-patient trial found 2.4 percent of patients on prasugrel suffered at least one major bleeding event, compared with 1.8 percent of patients on Plavix, which Bristol markets with Sanofi-Aventis (SASY.PA).

"When it comes to anti-clotting medications, there is no free lunch," said Deepak Bhatt, cardiologist and professor of medicine at the Cleveland Clinic, who wrote the editorial accompanying the study.

(Read content ‘Lilly clot drug linked to more bleeding in trial (Reuters)’…)

A new study released by Cutting Edge Information, available at , examines medical publication efforts of pharmaceutical companies across a wide range of therapeutic areas. (Read content ‘Pharmaceutical Companies Release Negative Trial Results On A More Regular Basis’…)